Greenwich LifeSciences/$GLSI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Greenwich LifeSciences
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
Ticker
$GLSI
Sector
Primary listing
Employees
6
Headquarters
Website
GLSI Metrics
BasicAdvanced
$379m
-
-$1.46
1.53
-
Price and volume
Market cap
$379m
Beta
1.53
52-week high
$34.10
52-week low
$7.78
Average daily volume
128k
Financial strength
Current ratio
2.347
Quick ratio
2.347
Profitability
EBITDA (TTM)
-19.584
Management effectiveness
Return on assets (TTM)
-254.19%
Return on equity (TTM)
-543.43%
Valuation
Price to book
172.92
Price to tangible book (TTM)
172.92
Price to free cash flow (TTM)
-42.513
Free cash flow yield (TTM)
-2.35%
Free cash flow per share (TTM)
-0.644
Growth
Earnings per share change (TTM)
80.07%
3-year earnings per share growth (CAGR)
37.37%
What the Analysts think about GLSI
Analyst ratings (Buy, Hold, Sell) for Greenwich LifeSciences stock.
GLSI Financial Performance
Revenues and expenses
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs